Combined pulmonary fibrosis and emphysema Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Combined pulmonary fibrosis and emphysema. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Combined pulmonary fibrosis and emphysema receives a directional strategic score of 71/100. The synthesis combines unmet need (86/100), competitive intensity (54/100, where a higher value means more competition) and market attractiveness (73/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A rare interstitial lung disease characterized by the coexistence of emphysema and usual interstitial pneumonia, typically occurring in male smokers. Emphysema is usually encountered in the upper lobes, preceding fibrosis of the lower lobes. Patients present with severe dyspnea and markedly reduced diffusion capacity on functional testing, while spirometric values are relatively preserved. The syndrome is frequently complicated by pulmonary hypertension and acute lung injury.

The reproducible entity is Patsnap disease ID 10daedcd5457489d96c5f45dfc0cd3f8. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Combined pulmonary fibrosis and emphysema, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: Chronic Obstructive Pulmonary Disease-Associated Mortality — China, 2014–2021 Chronic Obstructive Pulmonary Disease-AssociatedMortality — China, 2014–2021

Yin P, Wu JY, Wang LJ, Luo CL, Ouyang LH, Tang XT, et al. The burden of COPD in China and its provinces: findings from the global burden of disease study 2019. Front Public Health 2022;10:859499. https://doi-org.sutd.idm.oclc.org/10.3389/fpubh.2022.859499. 1. Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology 2015;20(8):1160 − 71. https://doi-org.sutd.idm.oclc.org/10.1111/resp.12642. 2. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet 2022;399(10342):2227 − 42. https://doi-org.sutd.idm.oclc.org/10.1016/S0140-6736(22)00470-6. 3. WHO. Chronic obstructive pulmonary disease (COPD). 2023. https:// www.who.int/news-room/fact-sheets/detail/chronic-obstructive- pulmonary-disease-(copd). [2023-3-16] 4. WHO. WHO report on the global tobacco epidemic 2021: addressing new and emerging products. Geneva: WHO; 2022. https://iris.who.int/ bitstream/handle/10665/343287/9789240032095-eng.pdf?sequence=1. 5. Han YT, He Y, Lyu J, Yu CQ, Bian MZ, Lee L. Aging in China: 6.

Review the underlying epidemiology source

Epidemiology signal 2: China CDC Weekly Reports (Vol. 7 No. 47 Nov. 21, 2025) Investing in Primary Care to Reduce the Burden ofChronic Obstructive Pulmonary Disease

COPD is a heterogeneous lung condition characterized by chronic respiratory symptoms accompanied by structural abnormalities of the airways and/or alveoli (1). Acute exacerbations — episodes of symptom worsening beyond normal day-to-day variation — can irreversibly diminish lung function and increase the frequency of subsequent exacerbations. Furthermore, patients with COPD face elevated risks of both respiratory and cardiovascular events that may result in premature mortality (2). As the most prevalent chronic respiratory disease globally, COPD now affects more than 300 million individuals worldwide and accounted for 3.3 million deaths in 2019 (3). China’s efforts to combat this disease carry particular global significance, as approximately one-third of all COPD-related deaths worldwide occur within the country (4). Prevalence of COPD in China COPD ranks as the third most prevalent non- communicable disease in China(5), following hypertension and type 2 diabetes, and currently affects 99.9 million people (6). Substantial regional disparities in disease burden exist, with higher prevalence rates observed in rural areas and among populations with lower educational attainment (7). At the provincial level, economically less developed regions demonstrate elevated COPD prevalence (8). The disease burden increases markedly with age, particularly in adults aged 50 years and above, with prevalence rates of 12.8% in males and 5.7% in females (9). Approximately 71% of patients experience exacerbations — defined as sustained worsening of symptoms beyond the usual stable state (10) — w

Review the underlying epidemiology source

Epidemiology signal 3: Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database Impact of the new definition for pulmonary hypertension inpatients with lung disease: an analysis of the United Networkfor Organ Sharing database

The implications of the recent change in the definition of pulmonary hypertension on epidemiology and outcomes are not known. We sought to determine the percentage of patients with the two most common lung diseases that would be reclassified regarding the presence/absence of pulmonary hypertension with the revised definition. A query of the United Network for Organ Sharing database was performed. The percentage of patients meeting the current and previous definition of pulmonary hypertension was described. Outcomes of patients stratified by the current and previous definitions were compared. There were 15,563 patients with right heart catheterization data analyzed. Pulmonary hypertension was more prevalent in both chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis under the new definition at 52.4% versus 82.4%, and 47.6% versus 73.6%, respectively. “Pre-capillary” pulmonary hypertension by the new definition was lower at 28.1% for chronic obstructive pulmonary disease and 36.8% for idiopathic pulmonary fibrosis. Of the patients with pulmonary hypertension by the old definition, 23.9% of chronic obstructive pulmonary disease patients and 18.7% of idiopathic pulmonary fibrosis patients were not classified as pulmonary hypertension by the new definition. Conversely, 15.9% of chronic obstructive pulmonary disease patients and 15.1% of idiopathic pulmonary fibrosis patients who did not meet diagnostic criteria for pulmonary hypertension by the old definition did have pulmonary hypertension by the new definition. Patients in both disease categories had shorte

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Combined pulmonary fibrosis and emphysema, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Combined pulmonary fibrosis and emphysema strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: ALK5

Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis (PubMed:33914044). The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.

The mechanism anchor for this landscape is TGFBR1. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 12 registered studies overall. Recent sampled records include:

• NCT07723638 — New Diagnostic Approaches in the Management of Inflammatory Lung Diseases (ALPI); status Not yet recruiting; phase Not Applicable; sponsor Fondazione Don Carlo Gnocchi Onlus; enrollment 200.
• ChiCTR2600119687 — Study of Staphylococcus and Neisseria Tablets for Combined Pulmonary Fibrosis and Emphysema (CPFE); status Not yet recruiting; phase Not Applicable; sponsor West China Hospital; enrollment 187.
• JPRN-jRCT2031240628 — Phase II/III study of MD-712; status Not Recruiting; phase Phase 2/3; sponsor Mochida Pharmaceutical Co., Ltd.; enrollment 15.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Combined pulmonary fibrosis and emphysema. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This negative signal can mean limited partnering momentum, a broader deal label or asset-level transactions not indexed to the exact indication. Target- and asset-based comparable searches should be added before valuation.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Combined pulmonary fibrosis and emphysema, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that TGFBR1 is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Combined pulmonary fibrosis and emphysema merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if TGFBR1 modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Combined pulmonary fibrosis and emphysema is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.